Citizens JMP analyst Roy Buchanan raised the firm’s price target on Enanta (ENTA) to $24 from $23 and keeps an Outperform rating on the shares. Enanta remains on track to report Phase 2 results for oral RSV therapeutic candidate zelicapavir in Q3, but has indicated that further development of it and RSV-polymerase inhibitor EDP-323 will be dependent on a partner, the analyst tells investors in a research note. The firm has removed RSV from its valuation.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENTA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue